Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Neoplasms 9Carcinoma, Hepatocellular 5Squamous Cell Carcinoma of Head and Neck 4Melanoma 3Colorectal Neoplasms 3Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Head and Neck Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sarcopenia 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myositis 1Metastatic Colorectal Adenocarcinoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Neoplasms 1Hyperthermia 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Heart Diseases 1Glioma 1Eye Diseases 1Esophageal Squamous Cell Carcinoma 1

Interventions

Carboplatin 49Etoposide 46Cisplatin 42Topotecan 39Irinotecan 21Paclitaxel 20Nivolumab 15pembrolizumab 13Gemcitabine 13atezolizumab 11Ipilimumab 11durvalumab 9Radiotherapy 9Doxorubicin 7Bevacizumab 7rovalpituzumab tesirine 6etoposide phosphate 6amrubicin 6Psychiatric Rehabilitation 6PM 01183 6Docetaxel 6Counseling 6trilaciclib 5Temozolomide 5Sunitinib 5Platinum 5Imatinib Mesylate 5Cyclophosphamide 5Bortezomib 5130-nm albumin-bound paclitaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Small Cell Lung Carcinoma × Immune Checkpoint Inhibitors × Clear all
NCT05509699 2025-08-29

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Hutchmed

Phase 2 Completed
21 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡